Personalized Treatment Selection for Metastatic Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Dasatinib|DRUG: AZD6244
Sponsor: M.D. Anderson Cancer Center
Collaborators: Bristol-Myers Squibb|AstraZeneca